EGFR and non-small cell lung carcinoma: Mazieres et al. reported that a study of ICI in EGFR mutant NSCLC regardless of receiving EGFR‐TKI treatment showed 2.1 months mPFS, ORR 12.2%, and DCR 33.1%.19